BOCA RATON, Fla. (PRWEB)
December 26, 2019
Florida Pharmaceutical Products, LLC. (FPP) a pharmaceutical company involved in the development Sales, Marketing and Distribution of Generic Pharmaceuticals and Agenix Pharmaceuticals, LLC a company involved in the development and licensing of pharmaceuticals are pleased to announce the signing of an agreement for the development, licensing, and Supply of an ANDA developed by Agenix to be filed with the FDA in 2020.
The product has sales of approximately $30 million according to IQVIA™ and limited generic competition. The ANDA product will be sold and Distributed by FPP in the FPP Label once approved. “We are excited to work with Agenix on this opportunity and look forward to filing this product next year,” said Larry J. Lapila, President of FPP. The ANDA will be manufactured by under a separate agreement by the CMO Woodfield Pharmaceutical, LLC in Houston, TX.
About Florida Pharmaceutical:
Florida Pharmaceutical Products, LLC. (FPP) is a Boca Raton based pharmaceutical company involved in the development of Generic Pharmaceuticals seeking to gain approval and/or license of niche generic products in a broad range of therapeutic areas for marketing and distribution in the US.
About Agenix:
Agenix Pharmaceuticals, LLC. is a Dallas, Texas based privately owned pharmaceutical company focused on development and marketing of niche generic prescription products in North America. Agenix is committed to provide high-quality, affordable pharmaceuticals to improve the health and quality of life of our customers and communities in the markets we serve. Please check http://agenixpharma.com/ for more information.
About Woodfield:
WDPrx – Woodfield Pharmaceutical, LLC provides end-to-end pharmaceutical outsourcing services from Research and Development, Material Procurement, Process Optimization, Formulation and Pharmaceutical Validation to Manufacturing, Analytics Testing, Regulatory Support, Primary and Secondary Packaging and Labeling.
Share article on social media or email: